Topline Phase 3 TRIUMPH-1 trial results show retatrutide drives a 30.3 percent body weight loss over 104 weeks of treatment.
Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody ...
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...
Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically ...
Galectin Therapeutics is a Buy as recent FDA alignment de-risks belapectin’s Phase 3 path and clarifies regulatory endpoints.
Results for Definium Therapeutics psychedelic candidate for major depressive disorder “exceeded expectations,” according to ...
Topline results from Phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-fr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results